Natural History of Spinal Muscular Atrophy Type 1 in Taiwan

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02466529

Enrollment

111

Registered

2015-06-09

Start date

2015-06-30

Completion date

2015-12-31

Last updated

2017-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Natural History of Type 1 Spinal Muscular Atrophy (SMA)

Keywords

type 1 spinal muscular atrophy (SMA)

Brief summary

Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by degeneration of motor neurons in the spinal cord and caused by mutations of the survival motor neuron 1 (SMN1) gene. The investigators will conduct a systematic review of the contents and activities collected via a comprehensive case report form. Patients who fulfilled diagnostic criteria for SMA type 1 will be reviewed retrospectively.

Detailed description

The primary objective of this study is to investigate the natural history of patients with spinal muscular atrophy (SMA) type 1 in Taiwan. This study will provide further insights into the clinical course and pathogenesis of SMA. Several analyses will be conducted regarding overall survival, respiratory support, feeding and nutritional support. The following outcome variables will be examined: correlation between SMA genotype and phenotype, survival, age of onset, and age of confirmed diagnosis, proportion of patients using non-invasive and invasive respiratory support, time to first use of respiratory support, proportion of patients on permanent ventilation, and time to permanent ventilation, number and average duration of hospitalizations, proportion of patients with gastrostomy, number of non-serious and serious respiratory infections, trend of growth parameter (e.g., body weight).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 36 Years

Healthy volunteers

Inclusion criteria

* Jan. 1979\ 30 Jun. 2014 diagnosed with Spinal Muscular Atrophy (SMA)Type 1 * Onset of paralytic floppy infant less than 6 months of age * Generalized hypotonia and symmetric weakness, which weakness is more severe in proximal than distal part of extremities * Weakness in the legs is greater than in the arms * Tendon reflexes are absent * Neurogenic changes in electromyogram and/or muscle pathology * SMN1 gene deletion or mutation

Exclusion criteria

* Non-5q SMA (no deletion or mutation of SMN1 gene) * SMA type 2, type 3 or type 4 (onset of SMA after 6 months of age)

Design outcomes

Primary

Measure	Time frame	Description
Age of death	up to 36 years	participants will be followed till the age of death

Secondary

Measure	Time frame	Description
Age of permanent ventilation	up to 36 years	participants will be followed till ventilation used 24 hours/day

Other

Measure	Time frame	Description
Clinical outcome with the following measures-1	up to 36 years	Age of onset
Clinical outcome with the following measures-2	up to 36 years	Copy numbers of SMN2 gene
Clinical outcome with the following measures-3	up to 36 years	Methods of Nutritional Supportive
Clinical outcome with the following measures-4	up to 36 years	Methods of Respiratory Supportive

Outcome results